PharmaSGP Holding SE - ESG Rating & Company Profile powered by AI
Browse to the end of the page for potential risks for PharmaSGP Holding SE based on industry, location and marketcap. If you are employed by PharmaSGP Holding SE and you wish to licence your Sustainability rating, please contact us. The ESG assessment for PharmaSGP Holding SE represents the company's transparency towards the UN SDGs.
PharmaSGP Holding SE in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 3.2, social score of 4.8 and governance score of 8.0.
5.3
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
645 | Biomm SA | 5.4 | High |
645 | Tiziana Life Sciences PLC | 5.4 | High |
658 | PharmaSGP Holding SE | 5.3 | High |
658 | Cellmid Ltd | 5.3 | High |
658 | Bio-Techne Corp | 5.3 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does PharmaSGP Holding SE have an accelerator or VC vehicle to help deliver innovation?
Does PharmaSGP Holding SE disclose current and historical energy intensity?
Does PharmaSGP Holding SE report the average age of the workforce?
Does PharmaSGP Holding SE reference operational or capital allocation in relation to climate change?
Does PharmaSGP Holding SE disclose its ethnicity pay gap?
Does PharmaSGP Holding SE disclose cybersecurity risks?
Does PharmaSGP Holding SE offer flexible work?
Does PharmaSGP Holding SE have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does PharmaSGP Holding SE disclose the number of employees in R&D functions?
Does PharmaSGP Holding SE conduct supply chain audits?
Does PharmaSGP Holding SE disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does PharmaSGP Holding SE conduct 360 degree staff reviews?
Does PharmaSGP Holding SE disclose the individual responsible for D&I?
Does PharmaSGP Holding SE disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does PharmaSGP Holding SE disclose current and / or historical scope 2 emissions?
Does PharmaSGP Holding SE disclose water use targets?
Does PharmaSGP Holding SE have careers partnerships with academic institutions?
Did PharmaSGP Holding SE have a product recall in the last two years?
Does PharmaSGP Holding SE disclose incidents of discrimination?
Does PharmaSGP Holding SE allow for Work Councils/Collective Agreements to be formed?
Has PharmaSGP Holding SE issued a profit warning in the past 24 months?
Does PharmaSGP Holding SE disclose parental leave metrics?
Does PharmaSGP Holding SE disclose climate scenario or pathway analysis?
Does PharmaSGP Holding SE disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does PharmaSGP Holding SE disclose the pay ratio of women to men?
Does PharmaSGP Holding SE support suppliers with sustainability related research and development?
Does PharmaSGP Holding SE disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does PharmaSGP Holding SE reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is PharmaSGP Holding SE involved in embryonic stem cell research?
Does PharmaSGP Holding SE disclose GHG and Air Emissions intensity?
Does PharmaSGP Holding SE disclose its waste policy?
Does PharmaSGP Holding SE report according to TCFD requirements?
Does PharmaSGP Holding SE disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does PharmaSGP Holding SE disclose energy use targets?
Does PharmaSGP Holding SE disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does PharmaSGP Holding SE have a policy relating to cyber security?
Have a different question?
Potential Risks for PharmaSGP Holding SE
These potential risks are based on the size, segment and geographies of the company.
PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.